Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
US Army
Baxter
Cerilliant
Citi
Harvard Business School
Johnson and Johnson
Argus Health
Julphar

Generated: October 23, 2018

DrugPatentWatch Database Preview

Rabeprazole sodium - Generic Drug Details

« Back to Dashboard

What are the generic sources for rabeprazole sodium and what is the scope of rabeprazole sodium patent protection?

Rabeprazole sodium is the generic ingredient in three branded drugs marketed by Cerecor Inc, Eisai Inc, Alkem Labs Ltd, Amneal Pharms, Aurobindo Pharma Ltd, Breckenridge Pharm, Dr Reddys Labs Ltd, Lannett Co Inc, Lupin Ltd, Mylan Pharms Inc, Teva Pharms Usa, and Torrent Pharms Ltd, and is included in twelve NDAs. Additional information is available in the individual branded drug profile pages.

There are thirty drug master file entries for rabeprazole sodium. Twenty-six suppliers are listed for this compound.

Pharmacology for rabeprazole sodium
Drug ClassProton Pump Inhibitor
Mechanism of ActionProton Pump Inhibitors
Medical Subject Heading (MeSH) Categories for rabeprazole sodium
Synonyms for rabeprazole sodium
(S)-Rabeprazole Sodium Salt
[2-[[4-(3-methoxypropoxy)-3-methyl-2-pyridyl]methylsulfinyl]benzimidazol-1-yl]sodium
1017795-22-0
117976-90-6
129982-41-8
171440-19-0
1H-Benzimidazole, 2-(((4-(3-methoxypropoxy)-3-methyl-2-pyridinyl)methyl)sulfinyl)-, sodium salt
1H-Benzimidazole, 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]methyl]sulfinyl]-, sodium salt (1:1)
1H-Benzimidazole,2-(((4-(3-methoxypropxy)-3-methyl-2-pyridinyl)methyl)sufinyl)-,sodium salt
1H-Benzimidazole,2-[[[4-(3-methoxypropoxy)- 3-methyl-2-pyridinyl]methyl]sulfinyl]-,sodium salt
2-(((4-(3-Methoxypropoxy)-3-methyl-2-pyridyl)methyl)sulfinyl)benzimidazole sodium salt
2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]-methyl]sulfinyl]-1 H -benzimidazole sodium salt
226904-80-9
976R906
AB0013367
AC-715
AC1Q1W5D
Aciphex (TN)
Aciphex Sodium
Aciphex Sprinkle
AK-94764
AKOS015895734
AKOS015962116
AKOS025310160
AM81231
AN-15565
API0004026
AS-13338
AX8150186
BC208315
BG0517
C07865
C18H20N3NaO3S
C18H20N3O3S.Na
CAS-117976-90-6
CCG-213574
CHEBI:8769
CHEMBL1200930
CR0021
CTK8E9030
D00724
DR002161
DSSTox_CID_24205
DSSTox_GSID_44205
DSSTox_RID_80118
DTXSID3044205
E 3810
E3810
EX-A176
FT-0631090
H932
Habeprazole Sodium
HMS2093H10
HMS2231E04
HMS3373B05
J-010726
J10481
KB-301660
KRCQSTCYZUOBHN-UHFFFAOYSA-N
KS-00000H0Y
LS-172366
LY 307640 sodium
LY-307640
LY307640 sodium
MFCD02092688
MLS001165734
MLS006010621
MolPort-003-850-098
MolPort-003-986-282
natrium-2-({[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methyl}sulfinyl)benzimidazol-1-id
NCGC00159518-02
NCGC00159518-05
NCGC00255838-01
Pariet
Pariet (TN)
pariete
Pariprazole sodium
Pepcia
Q-201655
R0115
Rabeprazole sodium (JP17/USAN)
Rabeprazole sodium [USAN]
Rabeprazole sodium salt
Rabeprazole sodium, >=98% (HPLC)
Rabicip
Rebeprazole sodium
Rebeprazole sodium salt
Rebeprazole sodium;
RTC-063564
S-7685
s4665
SC-19471
SCHEMBL140494
SMR000550493
sodium 2-({[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methyl}sulfinyl)benzimidazol-1-ide
sodium 2-[[4-(3-methoxypropoxy)-3-methyl-2-pyridyl]methylsulfinyl]benzimidazol-1-ide
SODIUM RABEPRAZOLE(1-)
sodium;2-[[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methylsulfinyl]benzimidazol-1-ide
ST24049115
ST51052899
TC-063564
TL8000495
Tox21_111736
Tox21_111736_1
Tox21_302317

US Patents and Regulatory Information for rabeprazole sodium

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Aurobindo Pharma Ltd RABEPRAZOLE SODIUM rabeprazole sodium TABLET, DELAYED RELEASE;ORAL 205761-001 Feb 17, 2017 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Eisai Inc ACIPHEX rabeprazole sodium TABLET, DELAYED RELEASE;ORAL 020973-001 May 29, 2002 DISCN Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Lupin Ltd RABEPRAZOLE SODIUM rabeprazole sodium TABLET, DELAYED RELEASE;ORAL 078964-001 Nov 8, 2013 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for rabeprazole sodium

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Cerecor Inc ACIPHEX SPRINKLE rabeprazole sodium CAPSULE, DELAYED RELEASE;ORAL 204736-001 Mar 26, 2013 ➤ Sign Up ➤ Sign Up
Eisai Inc ACIPHEX rabeprazole sodium TABLET, DELAYED RELEASE;ORAL 020973-002 Aug 19, 1999 ➤ Sign Up ➤ Sign Up
Eisai Inc ACIPHEX rabeprazole sodium TABLET, DELAYED RELEASE;ORAL 020973-001 May 29, 2002 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
US Army
Baxter
Cerilliant
Citi
Harvard Business School
Johnson and Johnson
Argus Health
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.